Jennifer Richer has developed a miRNA screen for identifying triple-negative breast cancers. The team has identified 5 miRNAs that are mysregulated in triple-negative breast cancer that can be used to determine if a sample is triple-negative. By screening for miRNA levels that are related to estrogen and growth factor signaling molecules and comparing them to miRNA expression levels of luminal breast cancer cells the inventors are able to classify a cancer as triple-negative or ER positive. Their screening also provides the possibility of treating the identified cancers with the screened miRNAs. From the screening results, miRNA treatment to correct the mysregulated miRNAs can be tailored to each patient.
To read a non-confidential summary of this technology, please click the image above. For more CU technologies available for licensing, please visit our Tech Explorer site.
1 day ago